+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Digital Landscape: Psoriatic Arthritis

  • ID: 4620760
  • Report
  • August 2018
  • Region: Global
  • 150 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie
  • BMS
  • Eli Lilly
  • MSD / Merck
  • Novartis
  • Sandoz
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Digital Landscape: Psoriatic Arthritis

Summary

"Digital Landscape: Psoriatic Arthritis", analyzes digital activities undertaken by pharma in support of therapies for active psoriatic arthritis (PsA)

The report includes digital activities directed towards patients and/or HCPs.

The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain).

Key Highlights

  • US Patients: AbbVie offers the strongest support for PsA patients in the US, with activity across all channels; most activity in 2017 detected in the branded space following license extensions in PsA, and new advertising campaigns seen for Cosentyx and Enbrel in PsA, while Janssen launched a Remicade-branded counter-biosimilar campaign. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app.

  • US HCPs: Good branded support available for US HCPs in PsA, but advertising focus is on other indications. A number of brand sites were updated with PsA content in 2017. Unbranded and mobile app landscapes are sparse, and opportunities may exist to develop or sponsor content with trusted non-pharma organizations. Social media activity is restricted to corporate accounts, with examples of HCP-specific accounts seen in other diseases.

  • EUCAN Patients: Good branded support is available for PsA patients in Germany, the UK, and Canada. Unbranded support is strongest from AbbVie, Novartis and Janssen, however no multi-country, local-language campaigns detected. PsA patients have access to a number of mobile apps, but many are branded or are multi-condition. UCB provides the only example of a PsA-specific mobile app in Europe

  • EUCAN HCPs: The EUCAN HCP landscape is underdeveloped, with little activity seen past branded. The unbranded and mobile app landscapes are particularly sparse, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.

  • Companies Mentioned: AbbVie, Novartis, Celgene, Janssen, Amgen, MSD / Merck, UCB, BMS, Pfizer, Eli Lilly, Sandoz, Mylan.



Scope

  • This report analyzes digital activities undertaken by pharma in support of therapies for therapies for active psoriatic arthritis (PsA).

  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.

  • The report is based on analysis conducted by a combination of digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.

  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.

  • This report covers the research period from January - December 2017.



Reasons to buy

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital PsA space, and can assist our pharma clients derive value in a number of ways:

  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in PsA

  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns

  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands

  • Business Development & Licensing: Assess topics and trends shaping digital health in PsA and beyond, and learn about key patient and physician online activities in PsA.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • BMS
  • Eli Lilly
  • MSD / Merck
  • Novartis
  • Sandoz
Executive Summary
Recent Developments
Landscape & Analysis
US: Patient-directed Activities
US HCP-directed Activities
EUCAN Patient-directed Activities
EUCAN HCP-directed Activities
Methodology
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:


  • AbbVie

  • Novartis

  • Celgene

  • Janssen

  • Amgen

  • MSD / Merck

  • UCB

  • BMS

  • Pfizer

  • Eli Lilly

  • Sandoz

  • Mylan

Note: Product cover images may vary from those shown